Difference between revisions of "Mutual Recognition Agreements"

From Powerbase
Jump to: navigation, search
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
[[Globalisation: European Commission and the Pharmaceutical Industry]]
+
This is the activity of [[European Commission]] whereby in the context of the EU pharmaceutical industry, MRAs faciliate the international trading of pharmaceutical products.  Essentially, MRAs set out the conditions between the EU and other countries in the trading and promoting of pharmaceuticals.  The Commission's pharmaceutical unit play an important role in actively promoting the trading of such products between the EU and countries on a global scale, e.g. Canada, the US, Australia, New Zealand, Switzerland and Japan. <ref> European Commission [http://ec.europa.eu/enterprise/pharmaceuticals/mra/index.htm MRA] Accessed 1/03/08 </ref> <ref> European Commission [http://ec.europa.eu/enterprise/international/index_en.htm Mutual recognition agreements] Accessed 1/03/08 </ref> <ref> European Commission [http://ec.europa.eu/enterprise/pharmaceuticals/mra/doc/statusreport20030717 Pharmaceuticals: regulatory framework and market authorisations.pdf] Accessed 1/03/08 </ref>
 
 
 
 
This is the activity of European Commission whereby in the context of the EU pharmaceutical industry, MRAs faciliate the international trading of pharmaceutical products.  Essentially, MRAs set out the conditions between the EU and other countries in the trading and promoting of pharmaceuticals.  The Commission's pharmaceutical unit play an important role in actively promoting the trading of such products between the EU and countries on a global scale, e.g. Canada, the US, Australia, New Zealand, Switzerland and Japan. <ref> MRA http://ec.europa.eu/enterprise/pharmaceuticals/mra/index.htm Accessed 1/03/08 </ref> <ref> Mutual recognition agreements http://ec.europa.eu/enterprise/international/index_en.htm Accessed 1/03/08 </ref> <ref> Pharmaceuticals: regulatory framework and market authorisations http://ec.europa.eu/enterprise/pharmaceuticals/mra/doc/statusreport20030717.pdf Accessed 1/03/08 </ref>
 
  
 
==Notes==
 
==Notes==
  
 
<references/>
 
<references/>

Latest revision as of 10:48, 18 May 2008

This is the activity of European Commission whereby in the context of the EU pharmaceutical industry, MRAs faciliate the international trading of pharmaceutical products. Essentially, MRAs set out the conditions between the EU and other countries in the trading and promoting of pharmaceuticals. The Commission's pharmaceutical unit play an important role in actively promoting the trading of such products between the EU and countries on a global scale, e.g. Canada, the US, Australia, New Zealand, Switzerland and Japan. [1] [2] [3]

Notes

  1. European Commission MRA Accessed 1/03/08
  2. European Commission Mutual recognition agreements Accessed 1/03/08
  3. European Commission Pharmaceuticals: regulatory framework and market authorisations.pdf Accessed 1/03/08